Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01787747




Registration number
NCT01787747
Ethics application status
Date submitted
6/02/2013
Date registered
11/02/2013
Date last updated
26/06/2014

Titles & IDs
Public title
Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
Scientific title
A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers
Secondary ID [1] 0 0
12-AVR-132
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Cohorts A and C - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts B and D - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts E and F - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts G and I - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts H and J - Single dose (D1) followed by twice daily dosing for 7 days
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Plasma concentrations of parent and metabolites
Timepoint [1] 0 0
8 Days
Secondary outcome [1] 0 0
Safety and tolerability
Timepoint [1] 0 0
8 days

Eligibility
Key inclusion criteria
* Healthy adult males
* 18 - 45 years of age
* BMI 18 - 30 kg/m2
Minimum age
18 Years
Maximum age
45 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
* History or presence of significant disease
* History of substance and/or alcohol abuse within the past 3 years
* Use of tobacco-containing or nicotine-contining products within 6 months
* Use of any prescription of over-the-counter (OTC) medication within 14 days

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2013
Sample size
Target
Accrual to date
Final
48
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Avanir Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To assess the single- and multiple-dose pharmacokinetic (PK), safety and tolerability of AVP-786 in healthy volunteers.
Trial website
https://clinicaltrials.gov/study/NCT01787747
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sepehr Shakib, MD
Address 0 0
CMAX
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01787747